JERUSALEM--(BUSINESS WIRE)--Jan. 1, 2006--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the Company’s ANDA for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg. Upon final approval, Teva’s Simvastatin Tablets will be the AB-rated generic equivalent of Merck’s Zocor(R) Tablets, a product indicated for the treatment of high cholesterol.
